![closeup_By_Jean-Etienne_Minh-Duy_Poirrier_from_Bruxelles_Belgium_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons closeup_By_Jean-Etienne_Minh-Duy_Poirrier_from_Bruxelles_Belgium_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons](../news/img/healthcare/closeup_By_Jean-Etienne_Minh-Duy_Poirrier_from_Bruxelles_Belgium_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons.jpg)
For the most recent fiscal period company increased a shortfall per share of $-0.10 per share compare to $-0.04 a year prior and advanced shortfall from $-0.08 per share from the previous reporting period.
Revenues decreased admirably by -12.426 % to $
0.31 millions from $0.35 millions in the corresponding reporting period a year prior and sequentially Revenue doubled by 697.172 % from $0.04 millions.
For the most recent fiscal period Vistagen Therapeutics Inc. realized net shortfall of $-19.776 million, higher than $-8.106 million a year ago.
Vistagen Therapeutics Inc. is expected to report next financial results on November 09, 2022.